There are hints, for example, that the alglucosidase-alfa enzyme replacement therapy used for the treatment of patients with Morbus Pompe might also be beneficial for patients with PRKAG2-associated glycogen storage disease [38]. The gene discussed is PRKAG2; the disease is Glycogen storage disease due to glycogenin deficiency.